CD19 CAR mRNA enables the expression of a chimeric antigen receptor (CAR) targeting CD19, a B cell specific surface marker, when transfected into T cells. In CAR-T therapy systems, when co-cultured with autologous T cells and activated through CD3/CD28, the CAR construct binds to CD19 on malignant B cells via its single-chain variable fragment (scFv), triggering T cell activation and cytotoxic killing through CD3ζsignaling and co-stimulatory domains.

• Used in CAR-T cell therapy.

• Sequence optimized and selected for high expression.

• Oligo-dT purification ensuring high quality and purity.

• Carefully controlled processes to minimize batch-to-batch variation.